CAR- T cell the new treatment in lymphoid neoplasia

by, A. Ivanaj, A. Cili, A. Perolla, P. Pulluqi, E. Calliku T. Caja, E. Pepa, R. Roxhani, T. Dedej

Abstract

CAR T-cell therapy. A type of treatment in which a patient’s T cells (a type of immune cell) are changed in the laboratory so they will bind to cancer cells and kill them. Blood from a vein in the patient’s arm flows through a tube to an apheresis machine (not shown), which removes the white blood cells, including the T cells, and sends the rest of the blood back to the patient. Then, the gene for a special receptor called a chimeric antigen receptor (CAR) is inserted into the T cells in the laboratory. Millions of the CAR T cells are grown in the laboratory and then given to the patient by infusion. The CAR T cells are able to bind to an antigen on the cancer cells and kill them. In multicenter study, patients with refractory large B-cell lymphoma who received CAR T-cell therapy with axi-cel had high levels of durable response, with a safety profile that included myelosuppression, the cytokine release syndrome, and neurologic events. In the patients with ALL CAR T-cell therapy demonstrated very good response with a safety adviser site effects. CAR T-cell therapy is a safety and very promising treatment in lymphoid neoplasia.